CG:NASDAQThe Carlyle Group Inc. Analysis
Data as of 2026-03-13 - not real-time
$46.10
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at $46.10, well below its 20‑day SMA of 51.06, 50‑day SMA of 57.15 and 200‑day SMA of 57.58, indicating a persistent bearish trend. The RSI of 31.4 suggests the shares are approaching oversold territory, while the MACD line sits at –2.80 below the signal line, confirming bearish momentum. Volume is on an increasing trend, which often precedes a sharper move, and the price is hovering just above the identified support level of 44.83 with resistance near 55.65. Volatility is exceptionally high at over 52% 30‑day and beta exceeds 1.7, underscoring the stock’s sensitivity to market swings. Despite the technical weakness, the company reported a record fee‑related earnings of $1.24 billion in 2025 and revenue growth of roughly 94% year‑over‑year, delivering a profit margin of 20% and operating margin above 30%. Forward earnings are projected at $5.46 per share, driving the forward P/E down to 8.45, far below the current trailing P/E of 25.9 and the industry average of 16.4. The dividend yield of 3.09% with a payout ratio near 79% adds income appeal, but the negative operating cash flow and a debt‑to‑equity ratio above 190% raise sustainability concerns.
Analyst consensus is a “buy” with a median target of $67, implying upside of roughly 46%, yet the combination of high leverage, weak cash generation, and a bearish technical backdrop suggests caution. Investors should weigh the strong top‑line momentum and attractive forward valuation against the elevated risk profile before deciding on exposure.
Analyst consensus is a “buy” with a median target of $67, implying upside of roughly 46%, yet the combination of high leverage, weak cash generation, and a bearish technical backdrop suggests caution. Investors should weigh the strong top‑line momentum and attractive forward valuation against the elevated risk profile before deciding on exposure.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish technical indicators (price below all SMAs, RSI near oversold)
- High volatility and beta increasing price sensitivity
- Proximity to support level limiting downside risk
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Record fee‑related earnings and 94% revenue growth
- Forward P/E of 8.45 indicating significant upside
- Attractive dividend yield supporting total return
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strategic 2028 targets and diversified global portfolio
- High leverage and negative operating cash flow
- Sustained dividend but potential sustainability concerns
Key Metrics & Analysis
Financial Health
Revenue Growth93.90%
Profit Margin20.06%
P/E Ratio25.9
ROE14.10%
ROA3.62%
Debt/Equity196.87
P/B Ratio2.9
Op. Cash Flow$-3275500032
Industry P/E16.4
Technical Analysis
TrendBearish
RSI31.4
Support$44.83
Resistance$55.65
MA 20$51.06
MA 50$57.15
MA 200$57.58
MACDBearish
VolumeIncreasing
Fear & Greed Index72.59
Valuation
Target Price$67.56
Upside/Downside46.57%
GradeOvervalued
TypeBlend
Dividend Yield3.09%
Risk Assessment
Beta1.73
Volatility52.59%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.